Our Services
Medical Information
Helpful Resources
Published on: 1/30/2026
Farxiga treats type 2 diabetes, heart failure with reduced or preserved ejection fraction, and chronic kidney disease, including in many people without diabetes. It is an SGLT2 inhibitor that helps the kidneys excrete extra sugar and fluid, which improves blood sugar, modestly reduces weight and blood pressure, lowers heart failure hospitalizations and cardiovascular death, and slows CKD progression and the need for dialysis. There are several factors to consider, including who should avoid it and safety issues like genital or urinary infections, dehydration, and rare ketoacidosis, as well as how and when to take it; see the important details below to guide your next steps.
Farxiga (generic name: dapagliflozin) is a prescription medication that has become an important treatment option for several chronic conditions. Originally approved for type 2 diabetes, Farxiga is now also used to help manage heart failure and chronic kidney disease (CKD)—even in some people who do not have diabetes.
This guide explains how Farxiga works, what it is used for, who may benefit, and what to know about safety—using clear, everyday language and information based on well-established medical research and regulatory guidance.
Farxiga belongs to a class of medicines called SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors).
Because of these effects, Farxiga does more than just lower blood sugar.
Farxiga is commonly prescribed for:
Each use is explained in more detail below.
For people with type 2 diabetes, Farxiga helps lower blood sugar levels by removing excess glucose through urine. It works independently of insulin, which makes it useful at many stages of diabetes.
Farxiga is not approved for type 1 diabetes and should not be used for diabetic ketoacidosis.
One of the most important newer uses of Farxiga is in heart failure, even for people without diabetes.
Large clinical trials have shown that Farxiga can:
Farxiga is approved for:
Farxiga:
These benefits are seen whether or not a person has diabetes.
Farxiga is also approved to slow the progression of chronic kidney disease.
Studies have shown Farxiga can significantly reduce the risk of:
Most people tolerate Farxiga well, but side effects can happen.
These risks are uncommon but important to recognize early.
Farxiga may not be appropriate for everyone.
Some of these symptoms can overlap with other conditions. You may want to consider doing a free, online symptom check for Diabetes Insipidus to better understand what might be going on.
Your doctor may adjust the dose or stop the medication temporarily during:
Do not stop Farxiga suddenly without medical advice, especially if you are taking it for heart failure or kidney disease.
Many people experience modest weight loss due to sugar and fluid loss, but it is not a weight-loss drug.
Yes, slightly. This can be helpful but may cause dizziness in some people.
Yes. It is approved for heart failure and chronic kidney disease in people without diabetes.
No. Farxiga helps manage chronic conditions and reduce risks, but it does not cure diabetes, heart failure, or kidney disease.
Farxiga is a versatile medication with proven benefits for:
It works by helping the body remove excess sugar and fluid through the kidneys, reducing stress on vital organs. For many people, it can improve quality of life and lower the risk of serious complications.
That said, Farxiga is not right for everyone. Side effects and risks—while uncommon—can be serious if ignored.
A healthcare professional can help determine whether Farxiga is appropriate for you and how to use it safely as part of a complete treatment plan.
(References)
* McCormack PL. Dapagliflozin: A Review in Type 2 Diabetes, Heart Failure and Chronic Kidney Disease. Drugs. 2022 Mar;82(4):469-484. PMID: 35147989.
* Rathi C, Jaiswal V, Gupta V, et al. Dapagliflozin: A SGLT2 Inhibitor with Pleiotropic Effects on Diabetes, Heart Failure, and Chronic Kidney Disease. Pharmaceuticals (Basel). 2022 Mar 29;15(4):418. PMID: 35402633.
* McMurray JJV, Solomon SD, Inzucchi SE, et al.; DAPA-HF Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. PMID: 31535829.
* Wiviott SD, Raz I, Bonaca MP, et al.; DECLARE-TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. PMID: 30427852.
* Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al.; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. PMID: 32971150.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.